NEW YORK, Sept. 23 (GenomeWeb News) - Perlegen Sciences said that Eli Lilly will increase its funding in support of the companies' ongoing pharmacogenomics research collaboration.

Under the partnership, which was struck in Dec. 2002, Perlegen is using its proprietary technology to genotype SNPs in clinical samples and discover genetic markers for Lilly.

Perlegen said that the increased funding is in addition to milestones and payments Lilly is making under the original deal.

Specific terms of the arrangement remain undisclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.